Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease - PubMed
. 2020 Jun;55(6):1194-1196.
doi: 10.1038/s41409-019-0662-6. Epub 2019 Sep 4.
Affiliations
- PMID: 31484991
- DOI: 10.1038/s41409-019-0662-6
Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease
Christopher Streiler et al. Bone Marrow Transplant. 2020 Jun.
No abstract available
Similar articles
-
Schoettler M, Duncan C, Lehmann L, Furutani E, Subramaniam M, Margossian S. Schoettler M, et al. Bone Marrow Transplant. 2019 Jul;54(7):1158-1160. doi: 10.1038/s41409-019-0450-3. Epub 2019 Jan 25. Bone Marrow Transplant. 2019. PMID: 30683905 Free PMC article. Clinical Trial. No abstract available.
-
Uygun V, Karasu G, Daloğlu H, Öztürkmen S, Kılıç SÇ, Yalçın K, Çelen SS, Hazar V, Yeşilipek A. Uygun V, et al. Pediatr Blood Cancer. 2020 Apr;67(4):e28190. doi: 10.1002/pbc.28190. Epub 2020 Jan 25. Pediatr Blood Cancer. 2020. PMID: 31981413 Clinical Trial.
-
Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
Bondeelle L, Chevret S, Hurabielle C, Samy L, Goletto T, Costantini A, Sicre de Fontbrune F, Michonneau D, Socié G, Tazi A, Bouaziz JD, Bergeron A. Bondeelle L, et al. Biol Blood Marrow Transplant. 2020 Nov;26(11):2115-2120. doi: 10.1016/j.bbmt.2020.07.033. Epub 2020 Jul 29. Biol Blood Marrow Transplant. 2020. PMID: 32738501
-
Bronchiolitis obliterans and airways obstruction associated with graft-versus-host disease.
Epler GR. Epler GR. Clin Chest Med. 1988 Dec;9(4):551-6. Clin Chest Med. 1988. PMID: 3069287 Review.
-
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Müller KG. Uhlving HH, et al. Bone Marrow Transplant. 2012 Aug;47(8):1020-9. doi: 10.1038/bmt.2011.161. Epub 2011 Aug 29. Bone Marrow Transplant. 2012. PMID: 21874057 Review.
Cited by
-
Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, Fu H, Lai X, Liu L, Huang H. Zhao Y, et al. Front Pharmacol. 2021 Jun 28;12:668825. doi: 10.3389/fphar.2021.668825. eCollection 2021. Front Pharmacol. 2021. PMID: 34262450 Free PMC article.
-
Tamburro RF, Cooke KR, Davies SM, Goldfarb S, Hagood JS, Srinivasan A, Steiner ME, Stokes D, DiFronzo N, El-Kassar N, Shelburne N, Natarajan A; Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation Workshop Participants. Tamburro RF, et al. Ann Am Thorac Soc. 2021 Mar;18(3):381-394. doi: 10.1513/AnnalsATS.202001-006OT. Ann Am Thorac Soc. 2021. PMID: 33058742 Free PMC article.
-
Glanville AR, Benden C, Bergeron A, Cheng GS, Gottlieb J, Lease ED, Perch M, Todd JL, Williams KM, Verleden GM. Glanville AR, et al. ERJ Open Res. 2022 Jul 25;8(3):00185-2022. doi: 10.1183/23120541.00185-2022. eCollection 2022 Jul. ERJ Open Res. 2022. PMID: 35898810 Free PMC article. Review.
-
Treatment of steroid-refractory graft versus host disease in children.
Gottardi F, Leardini D, Muratore E, Baccelli F, Cerasi S, Venturelli F, Zanaroli A, Belotti T, Prete A, Masetti R. Gottardi F, et al. Front Transplant. 2023 Sep 15;2:1251112. doi: 10.3389/frtra.2023.1251112. eCollection 2023. Front Transplant. 2023. PMID: 38993897 Free PMC article. Review.
References
-
- Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302:306–14. - DOI
-
- Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:710–6. - DOI
-
- Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO Randomized Clinical Trial. JAMA. 2017;318:557–66. - DOI
-
- Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123:3832–42. - DOI
-
- Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, et al. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transpl. 2018;53:826–31. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources